Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Sundaram Multi Pap's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 115.73 | 121.6 | 134.58 |
| Cash Equivalents | 0.08 | Not available | Not available |
| Other Liabilities Total | 0.53 | 0.45 | 0.48 |
| Long Term Debt | 2.85 | 4.92 | 23.47 |
| Common Stock Total | 47.39 | 47.39 | 47.39 |
| Other Current Assets Total | 0.33 | 0 | 0 |
| Total Assets | 115.73 | 121.6 | 134.58 |
| Current Portof LT Debt/Capital Leases | 1.12 | 1.36 | 0.18 |
| Total Equity | 90.69 | 87.54 | 92.63 |
| Retained Earnings(Accumulated Deficit) | 43.3 | -47.01 | -41.92 |
| Total Common Shares Outstanding | 47.39 | 47.39 | 47.39 |
| Tangible Book Valueper Share Common Eq | 1.87 | 1.78 | 1.85 |
| Total Liabilities | 25.04 | 34.06 | 41.94 |
| Total Debt | 21.14 | 26.87 | 32.03 |
| Short Term Investments | 8.69 | 11.01 | Not available |
| Cashand Short Term Investments | 8.77 | 14.21 | 0.22 |
| Total Receivables Net | 13.6 | 21.65 | 23.41 |
| Notes Payable/Short Term Debt | 17.16 | 20.59 | 8.38 |
| Accounts Receivable-Trade Net | 13.47 | 14.69 | 11.88 |
| Property/Plant/Equipment Total-Net | 50.14 | 48 | 64.22 |
| Total Current Liabilities | 21.65 | 28.69 | 17.99 |
| Total Inventory | 40.66 | 33.68 | 41.22 |
| Accounts Payable | 0.26 | 2.85 | 6.64 |
| Other Currentliabilities Total | 3.1 | 1.48 | 1.09 |
| Total Long Term Debt | 2.85 | 4.92 | 23.47 |
| Intangibles Net | 1.98 | 0.81 | 2.07 |
| Other Long Term Assets Total | 0.26 | 0.35 | 0.3 |
| Total Current Assets | 63.35 | 70.22 | 65.01 |
| Accumulated Depreciation Total | Not available | -30.52 | -28.38 |
| Accrued Expenses | Not available | 2.42 | 1.7 |
| Prepaid Expenses | Not available | 0.67 | 0.16 |
| Additional Paid-In Capital | Not available | 87.16 | 87.16 |
| Cash | Not available | 3.21 | 0.22 |
| Property/Plant/Equipment Total-Gross | Not available | 78.51 | 92.61 |
| Goodwill Net | Not available | 2.23 | 2.97 |
PEG Ratio2.46
Price to Sale Ratio0.44
Debt 5Yr CAGR %-11.65
Operating Margin 12m1.92
Operating Margin 5y Avg0.96
Net Profit Margin 12m2.32
Net Profit Margin 5y-0.09
Dividend Yield %0
Overall RiskBalanced risk
Board Risk42.23
Only peers present in the company profile payload are displayed.
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Not available
Sundaram Multi Pap has the symbol SUNDARAM and ISIN - INE108E01023.
Sundaram Multi Pap is currently trading at INR 1.19.
Sundaram Multi Pap has a year high of INR 2.20 and a year low of INR 1.03.
Sundaram Multi Pap has a market capitalization of INR 60.18 crore.
Sundaram Multi Pap has a P/E ratio of 18.67.
Sundaram Multi Pap has a dividend yield of 0.00%.
Sundaram Multi Pap has revenue of INR 137.11 crore, net income of INR 3.18 crore, and EPS of INR 0.05.
Sundaram Multi Pap has a book value of INR 1.87.
Sundaram Multi Pap has a debt-to-equity ratio of NA.
Sundaram Multi Pap has a price-to-book ratio of 0.64 and a price-to-sales ratio of 0.44.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.